GLPwatch
The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia.
Curr Atheroscler Rep · 2022
Last updated 2026-05-28A review of studies found that GLP-1 receptor agonists (GLP-1 RAs) like exenatide, liraglutide, lixisenatide, semaglutide, and dulaglutide consistently reduced post-meal fat levels in the blood. For example, exenatide lowered post-meal triglycerides in 4 out of 6 studies, while liraglutide did so in all 2 studies examined.
AI summary of the abstract below.
| Journal | Curr Atheroscler Rep, 2022 |
|---|---|
| Citations | 17 |
| Relative citation ratio | 1.40 |
| NIH percentile | 62 |
| Molecules | — |
| Conditions studied | Obesity, Cardiovascular Risk Reduction |
Abstract
PURPOSE OF REVIEW: To review the currently available data on the effect of Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on postprandial lipaemia.
RECENT FINDINGS: Out of the available studies that examined the respective lipid parameter, exenatide reduced postprandial triacyglycerol (TAG) in 4/6, apolipoprotein B-48 in 3/3, non-esterified fatty acids in 2/2, and apolipoprotein C-III and very low-density lipoprotein cholesterol (VLDL-C) in 1/1 studies. Liraglutide reduced postprandial TAG in 2/2, apolipoprotein B-48 in 3/3 and apolipoprotein C-III, chylomicron-TAG and VLDL-TAG in 1/1 studies. Lixisenatide reduced postprandial chylomicron-TAG and apolipoprotein B-48 in 1 study. Semaglutide reduced postprandial TAG, apolipoprotein B-48 and VLDL in 1 study. Dulaglutide reduced postprandial apolipoprotein B-48 in 1 study. GLP-1 RAs have consistent beneficial effects on postprandial lipaemia with most of the data coming from studies with exenatide and liraglutide. Reduction of postprandial lipaemia might be one of the mechanisms behind the pleiotropic effects of GLP-1 RAs.
Verbatim abstract via PubMed 35080714 ↗